Reg Capital Advisors

Reg Capital Advisors

Reg Capital Advisors was established in 2011 by Oleg Nodelman, a biotech-focused investor whose personal capital forms the core of the vehicle. The firm operates as a family office structured around a high-conviction public-equities strategy, concentrating its balance sheet into underperforming biotechnology companies where it can push for operational turnarounds. Nodelman's approach emerged from deep sector specialization rather than institutional training, and the firm retains a lean footprint in San Francisco. The strategy centers on event-driven equity positions in small- and mid-cap biotech, healthcare services, and life-sciences tools companies. Nodelman typically takes stakes large enough to require Schedule 13D filings, which the firm uses as a platform to negotiate board representation, management changes, or strategic alternatives. Public filings show Reg Capital has engaged with companies including Echo Therapeutics and Biotie Therapies, where it pushed for governance reforms and accelerated licensing deals (per SEC filings, 2014-2016). The geographic focus is predominantly North America and Europe, with the firm's European targets often tied to cross-border licensing opportunities. As a single-principal office, Reg Capital does not disclose total assets under management or a headcount beyond Nodelman himself, though it has periodically co-invested alongside aligned activists and has demonstrated a willingness to participate in bridge financings for deeply discounted microcap biotechs. The firm has maintained a limited public profile, with no known philanthropic foundation or separate venture arm. Reg Capital's structure sits at an unusual intersection: it deploys family-office permanence — no redemption pressure, no quarterly benchmarks — with the aggressive governance playbook of an activist hedge fund. That pairing lets Nodelman hold positions through clinical-trial volatility that would shake out fund-of-funds allocators, while still demanding the governance levers that passive family offices usually leave untouched. The firm's ongoing small- and microcap focus means it operates in a liquidity pocket largely abandoned by institutional biotech funds, creating a structural sourcing advantage in pre-revenue life-sciences turnarounds.